Our purpose-built and configurable platform brings together everything your company needs to optimize the Third-Party Lifecycle.
Prevent overpayments before they occur. Learn more ↠
Working with this global pharmaceutical company, we have delivered $800m to the bottom line while preserving supplier relationships through automated mitigation of duplicate payments and a continuous rolling-window supplier statement review.

Financial outcomes:
Another apexanalytix client in the pharmaceutical industry, Charles River Labs, ensures financial accuracy and reclaims list value through our services.
In this testimonial, their Chief Procurement Officer, Gerard Cardillo, shares how we deliver insights as well as cash.
To read more about our partnership with Charles River Labs, click here.
Read how a nearly two-decade long partnership with a global biopharma audit continues to strengthen financial controls and unlock millions in recoveries.
The company’s scale—including a vast supplier network, billions in annual spend, and multiple divisions with differing approval workflows, system configurations, and operational requirements—creates a complex environment that demands rigorous financial oversight.
With invoices spanning multiple systems and regions, the risks of unclaimed credits and errors from purchase order changes are significant. Click here to read more.

Read how a statement review identified millions of Euros in overpayments that were missed by ERP controls.
This European headquartered pharmaceutical giant is a long-term client of apexanalytix. Their recent audit results highlight the limitations of transaction-level ERP controls.
During the latest audit period, apexanalytix reviewed €28.6bn in spend across more than 2 million invoices and over 60,000 vendors. Click here to read more.


Auditing closer to the transaction makes sure that we recover all overpayments timely. And insights from apexanalytix give us the information on where to focus and how to fix the gaps in our procure-to-pay process.Director, Global Process Owner – Invoice to Pay (major pharmaceutical company)